A Prospective Matched-Control Randomized Open-Label Flexible-Dose Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment with Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
Alan Breier, MD
Primary Investigator
Overview
The purpose of this study is to help understand if paliperidone palmitate or oral antipsychotic medication is better at preventing a worsening of the symptoms of schizophrenia or schizophreniform disorder which could cause an unfavorable outcome.
Description
The purpose of this study is to help understand if paliperidone palmitate or oral antipsychotic medication is better at preventing a worsening of the symptoms of schizophrenia or schizophreniform disorder which could cause an unfavorable outcome.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
schizophrenia,schizophreniform disorder
-
Age: Between 18 Years - 35 Years
-
Gender: All
Inclusion Criteria
Has had first symptoms of psychosis within the past two years
Have a responsible person who will assist with telling the study staff how patient is doing
Have a stable place to live
